TargetBeta
FOLR1
folate receptor alpha · also FRα, FOLR · Folate receptors
7 programs in company-led studies act on FOLR1, from 5 companies: 4 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| rinatabart sesutecanrule | Genmab | phase 3 | 99 running | – | NCIt |
| mirvetuximab soravtansinerule | AbbVie | phase 3 | 158 running | – | NCIt |
| torvutatug samrotecan | AstraZeneca | phase 3 | 55 running | – | a judged reading |
| sofetabart mipitecan | Eli Lilly | phase 3 | 22 running | – | a judged reading |
| opugotamig olatansine | AbbVie | phase 2 | 22 running | – | the company's pipeline |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 11 running | – | the company's pipeline |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | TeneoSeven | phase 1 | 11 running | CD3E | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Ovarian Neoplasms, 6 programs
- Fallopian Tube Neoplasms, 4 programs
- Carcinoma, Ovarian Epithelial, 2 programs
- Endometrial Neoplasms, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Gastrointestinal Neoplasms, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026mirvetuximab soravtansine · AbbVie · phase 3 · NCT05456685
- Feb 2027opugotamig olatansine · AbbVie · phase 2 · NCT05527184
- Sep 2027rinatabart sesutecan · Genmab · phase 3 · NCT07604766
- Oct 15, 2027torvutatug samrotecan · AstraZeneca · phase 3 · NCT07402915
- Jun 2028Anti-FRa/Anti-CD3 Bispecific TCE NTB-928 · TeneoSeven · phase 1 · NCT07690189
- Nov 2028sofetabart mipitecan · Eli Lilly · phase 3 · NCT07213804
- Dec 2028Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 · AbbVie · phase 1 · NCT07278336
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.